Goldman Sachs
PAVM icon

Goldman Sachs’s PAVmed PAVM Stock Holding History

Goldman Sachs’s Portfolio PAVM Stock Details PAVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-171
Closed -$72K – 6463
2022
Q2 		$72K Sell
171
-127
-43% -$61.4K ﹤0.01% 5950
2022
Q1 		$178K Sell
298
-630
-68% -$468K ﹤0.01% 5926
2021
Q4 		$1.03M Buy
928
+591
+175% +$1.28M ﹤0.01% 4815
2021
Q3 		$1.3M Buy
337
+179
+113% +$564K ﹤0.01% 4553
2021
Q2 		$456K Buy
158
+26
+20% +$61.4K ﹤0.01% 5276
2021
Q1 		$263K Sell
132
-11
-8% -$16.5K ﹤0.01% 5495
2020
Q4 		$136K Buy
143
+100
+233% +$85.5K ﹤0.01% 5227
2020
Q3 		$34K Buy
+43
New +$38.3K ﹤0.01% 5221
2017
Q4 		– Sell
-60
Closed -$146K – 6563
2017
Q3 		$146K Buy
+60
New +$124K ﹤0.01% 5906

Other funds holding PAVM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Goldman Sachs's PAVM Position: Q3 2022 in Review

Goldman Sachs sold out of PAVmed (PAVM) in Q3 2022, closing a stake of 171 shares — an estimated $72K sold.

Goldman Sachs first reported a position in PAVM in Q3 2017 and held it in 9 quarters. The position peaked at $1.3M in Q3 2021. 70 funds tracked by Wall St. Rank hold PAVM as of Q3 2022.

  • Goldman Sachs reported no remaining PAVmed position as of Q3 2022 after selling out during the quarter.
  • Goldman Sachs sold 171 PAVmed shares in Q3 2022, an estimated $72K.
  • Goldman Sachs first reported a position in PAVmed in Q3 2017 and held it in 9 quarters.
  • Goldman Sachs's PAVmed position peaked at $1.3M in Q3 2021.
  • 70 funds tracked by Wall St. Rank held PAVmed as of Q3 2022.

Based on Goldman Sachs's 13F filing for Q3 2022, filed 14 Nov 2022.